Comparison of Pharmacokinetic Characteristics of Bilosomal Dispersion Versus Pure Solution of Oral Ropinirole Hydrochloride in Rats
DOI:
https://doi.org/10.32007/jfacmedbagdad.6622210Keywords:
Bilosomes; , Bioavailability;, nanovesicular carriers; , Pharmacokinetics;, Ropinirole hydrochloride.Abstract
Background: Ropinirole hydrochloride is a non-ergoline antiparkinson drug. It is a highly hydrophilic drug and classified as class III according to Biopharmaceutical Classification System with low absolute oral bioavailability of approximately 50% upon oral administration due to significant hepatic first-pass metabolism.
Objective: to compare the pharmacokinetic parameters of Ropinirole, when administered orally in the form of a Ropinirole bilosomal dispersion in contrast to an oral Ropinirole solution.
Methods: This study involved the use of twelve male Wistar rats, with an average weight of 220±11 g, and these rats were divided into two groups, comprising six rats each. A 1.1mg/kg doses of pure Ropinirole and Ropinirole bilosomes were administered orally through gavage after reconstituting in distilled water. Ropinirole was quantified in the rat's plasma using HPLC, subsequently establishing a spiked calibration curve with plasma samples and utilizing paracetamol as an internal standard. The statistics included mean values (± SD; n = 6) for pharmacokinetic parameters, with statistical significance assessed using a Student's t-test.
Results: For the oral bilosomes, the values were 9.4±0.11 μg /ml for Cmax, 3±0.00 h for Tmax, and 55.56±2.12 μg h/ml for AUC0-24. In contrast, for the oral solution, the corresponding values were 7.2±0.14 μg/ml for Cmax, 1.5±0.00 h for Tmax, and 23.70±2.23 μg h/ml for AUC0-24. These parameters were significantly higher (P<0.05) as compared with a pure drug solution. The comparative bioavailability of Ropinirole (AUC0-24 oral solution / AUC0-24 oral bilosomes ) is equal to 42.66%, which indicates the bioavailability of the oral RH solution was less than that of RH bilosomal dispersion.
Conclusions: The use of nano vesicular carriers (bilosomes) shows significant potential as an effective delivery system for improving the oral bioavailability of ropinirole hydrochloride
Downloads
References
Al-Taweel AF, Qasim AA. Prosthetic Status in Relation to Weight Status and Occupation among Parkinson's Disease Patients in Baghdad-Iraq. J Bagh Coll Dent. 2018 ;30(3):21-27. https://doi.org/10.26477/jbcd.v30i3.2527
Muslim AT, Ahmed AH, Zaer NH, Hasan ZN. Non-Motor Symptoms In Patients With Parkinson's Disease In Baghdad Hospitals. Al-Kindy Col. Med. J 2017;13(1):122-7. https://doi.org/10.47723/kcmj.v13i1.141.
Zesiewicz TA, Chriscoe S, Jimenez T, et al. A fixed-dose, dose–response study of ropinirole prolonged release in early-stage Parkinson's disease. Neurodegener Dis Manag 2017;7:49- 59. https://doi.org/10.2217/nmt-2016-0039.
Pardeshi CV, Belgamwar VS. Ropinirole-dextran sulfate nanoplex for nasal administration against Parkinson's disease: in silico molecular modeling and in vitro-ex vivo evaluation. Artif Cells Nanomed Biotechnol. 2017 May;45(3):635-648. https://doi.org/10.3109/21691401.2016.1167703.
Sadashivaiah R, Satheeshababu BK and Rohith G: A comparative evaluation of permeation enhancers for ropinirole hydrochloride, a BCS class III drug to be formulated as transdermal drug delivery system. Int J Pharm Sci & Res 2020; 11(12): 6149-56. doi: 10.13040/ IJPSR.0975-8232.11(12).6149-56.
Sadashivaiah R, Babu BKS. Role of sodium l-cysteine alginate conjugate and isopropyl myristate to enhance the permeation enhancing activity of BCS class III drug from TDDS; optimization by central composite design and in vivo pharmacokinetics study. Drug Dev Ind Pharm. 2020;46(9):1427-1442. https://doi.org/10.1080/03639045.2020.1791167.
Moffat A, Osselton M, Widdop B. Clarke's Analysis of Drugs and Poisons. 4th edition. The Pharmaceutical Press 2011; p- 2030. ISBN9780853697114.
Ali SK, Al-Akkam EJ. Effects of different types of bile salts on the physical properties of ropinirole-loaded bilosomes. Al-Rafidain J Med Sci. 2023;5:134-142. https://doi.org/10.54133/ajms.v5i.176.
Nemr AA, El-Mahrouk GM, Badie HA. Hyaluronic acid-enriched bilosomes: an approach to enhance ocular delivery of agomelatine via D-optimal design: formulation, in vitro characterization, and in vivo pharmacodynamic evaluation in rabbits, Drug Delivery.2022;29(1): 2343-2356. https://doi.org/10.1080/10717544.2022.2100513.
Smail SS, Ghareeb MM, Omer HK, Al-Kinani AA, Alany RG. Studies on surfactants, cosurfactants, and oils for prospective use in formulation of ketorolac tromethamine ophthalmic nanoemulsions. Pharmaceutics. 2021;13:467. https://doi.org/10.3390/pharmaceutics13040467
Gupta DK, Abdul Ahad, Ayesha Waheed MA, Al-Jenoobi FI, Al Mohizea AM. Bilosomes: a novel platform for drug delivery. In: Nayak AK, (Ed.), Systems of Nanovesicular Drug Delivery, (1st ed.), Academic Press; 2022. p. 293–309. http://dx.doi.org/10.1016/B978-0-323-91864-0.00004-8.
Srinivas Bhairy et al. Stability and in-vivo efficacy of bile salts containing vesicles (bilosomes) for oral delivery of vaccines and poorly soluble active drug molecules. Indo American Journal of Pharmaceutical Research.2020;10(10):1326-1334.http://dx.doi.org/10.5281/zenodo.4066496
Li Di EHK. Pharmacokinetics. In: Li Di EHK, editor. Drug-Like Properties. 2nd ed. Academic Press; 2017. p. 267–81. ISBN: 9780128013229.
Al-Tamimi DJJ, Al-kinani KK, Taher SS, Hussein AA. Effect of Food on the Pharmacokinetics of Fluoxetine in Healthy Male. Iraqi J Pharm Sci, 2022;31:153–61. https://doi.org/10.31351/vol31issSuppl.
Salih OS, Al-Akkam EJ. Pharmacokinetic parameters of ondansetron in rats after oral solution and transdermal invasomes gel: A comparison study. J.Adv.Pharm.Educ.Res.2023;13(1):116-21. https://doi.org/10.51847/HS5a27EI6o.
Elnaggar YSR, Omran S, Hazzah HA, Abdallah OY. Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate. Int J Pharm. 2019;10(564):410-425. https://doi.org/10.1016/j.ijpharm.2019.04.069.
Azeem A, Talegaonkar S, Negi LM, Ahmad FJ, Khar RK, Iqbal Z. Oil-based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. Int J Pharm. 2012 Jan 17;422(1-2):436-44. https://doi.org/10.1016/j.ijpharm.2011.10.039.
Dudhipala N, Gorre T. Neuroprotective effect of Ropinirole Lipid Nanoparticles Enriched Hydrogel for Parkinson's Disease: In-Vitro, Ex- Vivo, Pharmacokinetic and Pharmacodynamic Evaluation. 2020;1–24. https://doi.org/10.3390/pharmaceutics12050448.
Abdulqader AA, Rajab NA. Bioavailability study of Posaconazole in rats after oral Poloxamer P188 Nano-micelles and oral Posaconazole pure drug. J Adv Pharm Edu Res. 2023;13(2):140-3. https://doi.org/10.51847/Q59uyvRmY3
Sadashivaiah R, Rohith G, K SBB. Quantification of ropinirole hydrochloride in api and tablets by novel stability-indicating rp-hplc method: its validation and forced degradation studies. Int.J. Appl. Pharm. 2019;11(5):317–23. http://dx.doi.org/10.22159/ijap.2019v11i5.33759.
The United State Pharmacopeia (USP) 41, NF36. Convention Inc. Rockville, MD. 2018. ISBN:9781936424702, 1936424703.
U.S. Department of Health and Human Services FDA. USFDA. Guidance for Industry: Bioanalytical Method Validation. 2001. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf.
Ahmed OAA, Badr-Eldin SM. Development of an optimized avanafil loaded invasomal transdermal film: Ex vivo skin permeation and in vivo evaluation—Int J Pharm. 2019;570:118657. https://doi.org/10.1016/j.ijpharm.2019.118657.
Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306–14. https://doi.org/10.1016/j.cmpb.2010.01.007.
Hashim AA, Rajab NA. Anastrozole Loaded Nanostructured Lipid Carriers: Preparation and Evaluation. Iraqi J Pharm Sci. 2021;30(2):185-95. https://doi.org/10.31351/vol30iss2pp185-195.
Jelliffe RW, Schumitzky A, Bayard D, Fu X, Neely M. Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance. Ther Drug Monit. 2015;37(3):389-394. https://doi.org/10.1097/ftd.0000000000000168.
Migliari S, Sammartano A, Boss M, et al. Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [68Ga]Ga-NODAGA-Exendin-4 Produced by a Fully Automated Method.Molecules.2022;27(2):543.https://doi.org/10.3390/molecules27020543.
Saifi Z, Mir SR, Amin S. Bilosomes nanocarriers for improved oral bioavailability of acyclovir: A complete characterization through in vitro, ex-vivo and in vivo assessment. J Drug Deliv Sci Technol. 2020;57:101634. http://dx.doi.org/10.1016/j.jddst.2020.101634.
Zakaria MY, Fayad E, Althobaiti F, Zaki I, Abu Almaaty AH. Statistical optimization of bile salt deployed nanovesicles as a potential platform for oral delivery of piperine: accentuated antiviral and anti-inflammatory activity in MERS-CoV challenged mice. Drug Deliv. 2021;28(1):1150-1165. https://doi.org/10.1080/10717544.2021.1934190.
Zafar A, Alruwaili NK, Sarim S, Hadal N, Saad K, Afzal M, et al. Bioactive Apigenin loaded oral nano bilosomes: Formulation optimization to preclinical assessment. Saudi Pharm J. 2021;29(3):269–79. https://doi.org/10.1016%2Fj.jsps.2021.02.003.
Arafat M, Kirchhoefer C, Mikov M, Sarfraz M, Löbenberg R. Nanosized Liposomes Containing Bile Salt: A Vesicular Nanocarrier for Enhancing Oral Bioavailability of BCS Class III Drug. J Pharm Pharm. Sci. 2017;20(0):305-318. https://doi.org/10.18433/j3ck88.
Hegazy H, Amin MM, Fayad W, et al. TPGS surface modified bilosomes as boosting cytotoxic oral delivery systems of curcumin against doxorubicin-resistant MCF-7 breast cancer cells. Int J Pharm. 2022;619:121717. https://doi.org/10.1016/j.ijpharm.2022.121717.
Abhinav M, Neha J, Anne G., Bharti V., Role of novel drug delivery systems in bioavailability enhancement at a glance, Int. J. Drug Deliv.Technol. 2016; 6: 7–26. http://dx.doi.org/10.25258/ijddt.v6i1.8884.
Wang L, Huang X, Jing H, et al. Bilosomes as effective delivery systems to improve the gastrointestinal stability and bioavailability of epigallocatechin gallate (EGCG). Food Res Int. 2021;149:110631. https://doi.org/10.1016/j.foodres.2021.110631.
Elkomy MH, Eid HM, Elmowafy M, Shalaby K, Zafar A, Abdelgawad MA, et al. Bilosomes as a promising nano platform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats. Drug Deliv. 2022;29(1):2694-2704. https://doi.org/10.1080/10717544.2022.2110997
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Samer K. Ali, Entidhar J. Al-Akkam
This work is licensed under a Creative Commons Attribution 4.0 International License.